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A KINDRED with propensity to develop
ovarian and other types ofcancer has been
reported by one of us (H.T.L.) (Lynch et
al., 1981). The inordinately high frequency
of individuals with low serum IgA levels
(Schuelke et al., 1982) in this kindred is
consistent with the numerous observations
of altered immune functions associated
with ovarian cancer in the general popula-
tion (Badger et al., 1981; Daunter et al.,
1979; Gerber et al., 1977; Hess et al., 1979;
Hughes 1971; Humphrey et al., 1977;
Mandell et al., 1979; Mantovani et al.,
1980a, b; Mikulski et al., 1977; Pattillo
et al., 1979a, b; Poulton et al., 1978; Ueda
et al., 1978, 1979). We here report the
results oftests relative to cellular immune
functions in this kindred.
Informed consent was obtained before
blood was taken from kindred members
and control population donors who resided
near this midwestern kindred. Lympho-
cytes were isolated and stimulated with
mitogens in microculture as previously
reported (Chaperon, 1982) except that:
(1) the base medium was RPMI 1640
(Grand Island Biological Co., Grand
Island, NY, U.S.A., and (2) in some
cultures, thefoetal calfserum wasreplaced
with serum autologous to the lymphocyte
donor. The ability of subjects' sera to
inhibit antibody-dependent cellular cyto-
toxicity (ADCC) of chicken red blood cells
and natural killer (NK) of K562 cells by
normal donor lymphocytes was assessed
by a 5ICr (New England Nuclear Corp.,
Boston, MA, U.S.A.) release assay. Assays
were modified from standard methods
(Garovoy & Carpenter, 1980). Heat-inacti-
vated test serum was added to a final
concentration of 11%, and supernatants
collected with a Skatron filter collection
system (Flow Laboratories, Hamden, CT,
U.S.A.). Inhibition was defined as test
CPM release less than the control release
minus 2 s.d. PHA-induced blast cells from
inhibited effectors were used as potential
ADCC targets to detect antibodies against
histocompatibility antigens. Serum inhibi-
tion of E rosettes was assessed by
preincubating normal donor lymphocytes
for 1 h at 4°C, washing, and testing the
cells for rosette formation with washed
sheep red blood cells. Typing for HLA
antigens was kindly provided by Dr Paul
Terasaki. Skin tests for delayed hyper-
sensitivity were also performed with PPD,
SK-SD, and mumps antigens. Statistical
analysis was performed as previously
reported (Schuelke et al., 1982).
Nineteen individuals represented in
Table I and the Figure had intrinsically
low blastogenic responses to one or more
mitogen when cultured in media contain-
ing FCS. Three (111-9, 111-29, IV-14) ofthe
4 living cancer-patients (III-9, 111-29, III-
38, IV-14) had lowered lymphocyte activ-
ity several years after cancer surgery.
Benign breast disease in Individual 111-39
and advanced age (74 years) in IndividualC. S. SCHUELKE ET AL.
TABLE I.-Subjects whose lymphocytes gave responses below the normal range with one or
more mitogen in FCS-containing culture medium
Mitogen
Subject
II-15
111-6
III-7
III-8
111-9
III-10
III-12
III-16
III-17
III-22
III-29
III-31
III-33
111-34
111-39
IV-3
IV-9
IV-14
Medium
alone
72+ 451
54 + 38
39 + 19
78 + 22
68+ 11
69 + 61
93 + 60
99 + 73
10+8
145 + 13
235 + 168
101 + 13
82 + 63
43 + 1079
53 + 32
117 + 100
41 + 12
141 + 114
Con-A2
4439 + 267
17336 + 1143
12608 + 231
15508 + 3712
14344 + 1167
23548 + 1760
10466 + 857
23059+ 1713
25964 + 2619
4524 + 1365
21436+ 1872
40325 + 242
24959 + 1024
16143+ 1079
20560+ 876
36932 + 5498
38396 + 2995
35936 + 2697
PHA3
14366 + 601
ND5
17509+ 1154
14926+ 1578
16627 + 817
25225 + 6021
5321+ 366
22757 + 815
30917 + 4115
16509 + 6477
14588 + 2041
13110+ 2410
45895 + 2645
8603 + 762
16045+ 1034
42160+ 1474
32648 + 3811
23262 + 1087
1-Numbers represent mean CPM + 1 s.d.
2 Normal 950% range= 2-675 x 104-5-166 x 104 CPM.
3 Normal 95% range= 1-866 x 104-4-929 x 104 CPM.
4 Normal 95% range=4-07 x 103-3-868 x 104.
5-Culture lost due to microbial contamination.
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11-15 were the only other factors identi-
fied which might explain the other low
responses.
The probabilities of randomly selecting
a population with the observed number or
a more extreme number of individuals
below the normal ranges were calculated
to be P -- 0001, P 0-014 and P 2 x 10-8
for Con-A, PHA, and PWM respectively.
Table II and the Figure show that sera
from 12 subjects caused a lower blasto-
genic response to one or more mitogen,
even though the most common observa-
tion was unchanged or increased respon-
siveness. This suppressive activity was
evident in one cancer patient (111-9),
whose serum suppressed the responses of
all 3 mitogens. Inhibitory activity(ies)
were also present in 2 spouses (111-39, III-
50). The most common selective suppres-
sion was of Con-A responses (111-36, III-
48, 111-50, IV-9, IV-22, IV-35), followed
by PHA (111-20, 111-28, IV-17), while
selective PWM suppression was not obser-
ved. A sex-influenced trend for females
preferentially to express serum-mediated
mitogenic suppression is suggested by the
TABLE III.-Inhibition of NK effector by
family sera*
Serum
Control
111-4
"'I-5
111-10
111-17
111-22
111-29
111-33
111-35
111-39
IV-11
IV-13
IV-14
IV-36
%Maximal Cr5" releaset
56-9+2-6
46-50-7
42 - 9 + 2 - 0
43-5 + 2-7
40-2+0-1
40-8+ 1-8
44-7+0-5
43 -5+3-0
43 - 7 + 1-0
49-4+0-1
47-6+ 1-3
39 * 8 + 2 0
44 - 3 + 1- 7
42 -4 + 1- 7
* Onily the data on inhibitory sera aie piesented.
The other sera did not exceed control values by 2
s.d.
t Data presented as average % release+ s.d. Per-
centage release was calculated by the formula:
release= -R-SR x MR-SR
Where ER=experimental release, MR = maximal
release, and SR= spontaneous release.
fact that only 3 men (111-9, 111-20, 111-50)
showed such activity, although the sex
ratio of the family members sampled was
approximately equal.
Serum-mediated inhibition of NK act-
ivity (Table III and the Figure) was
presented in 11 bloodline individuals and 2
spouses (111-10, 111-39). NK inhibitory
activity occurred both concomitantly with
and independently of ADCC suppressor
activity, and was present in the 2 cancer
patients with lower serum IgA (111-29, IV-
14). Sera from 2 apparently wellgeneration
IV females (IV-13, IV-36) also inhibited
NK activity.
The Figure shows the 8 bloodline
individuals (111-5, 111-8, III-17, 111-20,
111-22, 111-52, IV-9, IV-32) whose sera
inhibited ADCC effector activity. None of
these sera had demonstrable antibodies
against the effector cells. Inhibitory act-
ivity was present in 2 younger generation
IV women (IV-9, IV-32). Based on the
results of sera samples from 300 mid-
western residents without a known ovar-
ian cancer propensity in their families, it
was predicted that 1 in 50 sera would be
inhibitory. Thus the probability of ran-
domly selecting a population with 8 or
more out of 50 individuals having the
activity is calculated to be P.- 3 2 x 10-4
(Fisher's exact test).
Three sera inhibited E-rosette formation
by normal donor T lymphocytes (111-9,
111-39, IV-14). Two sera were from cancer-
affected individuals (111-9, IV-14) and one
was from a spouse (111-39) subsequently
proven to have benign breast disease
yet who underwent mastectomy. Direct
assessment of E-rosette formation by
subjects' lymphocytes in the absence of
serum failed to reveal any abnormalities
not attributable to noncancerous condi-
tions.
No simple association was evident
between any single significant abnormal
immune finding and blood markers (ABO,
Duffy, HLA, or Rhesus antigens) present
in the kindred. Skin test results were
unremarkable.
Any close association between an im-
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munological parameter (or parameters)
and a cancer-prone genotype would aid
immeasurably in genetic counselling and
decision logic for surveillance and manage-
ment. Long-term follow-up will obviously
be needed to determine if any immune
parameter(s) identified in cancer families
are a constitutionally integral trait cor-
relating with cancer-predisposing geno-
type and eventual phenotypic expression
(clinical cancer).
The immune findings in spouses (111-10,
111-12, 111-39 and 111-50) could represent
either random findings unrelated to cancer
or a communicable environmental effect
(Byers et al., 1975; Dean et al., 1979;
Dworsky et al., 1978; Graham-Pole et al.,
1976; Guirgis et al., 1978; Hersey et al.,
1979). The following observations are
consistent with an association of immune
findings with cancer-prone genotype: (1)
predominance of mitogen suppressive act-
ivity in sera from high-risk females; (2)
instances of selective mitogen inhibition
by family sera similar to hepatocellular
carcinoma sera effects on mitogen respon-
ses (Ren & Chan, 1981) and (3) increased
frequency of ADCC and/or NK serum
inhibitory activity in older generation III
individuals and selective inhibition of one
killing activity by some sera is strikingly
similar to the results of a mouse tumour
study (Nair et al., 1980). Limitations in
sample size and the findings in a single
family restrict a more complete elucidation
of immunological mechanisms. Logistic
and other considerations have to date
prevented more extensive immunological
analysis than the assays performed as
reported above. However, we feel that
these data are sufficiently suggestive to
warrant further investigations of immune
function in other ovarian cancer-prone
kindreds in an attempt to identify both a
precancerous marker (or markers) and to
define further possible aetiological rela-
tionships between immune functions and
hereditary cancer.
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